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Background. The impact of obesity on survival in end-stage
renal disease (ESRD) patients as related to dialysis modality
(i.e., a direct comparison of hemodialysis with peritoneal dial-
ysis) has not been assessed adjusting for differences in med-
ication use, follow-up ≥2 years, or accounting for changes in
dialysis modality.
Methods. We performed a retrospective cohort study of the
United States Renal Data System (USRDS) Dialysis Morbid-
ity and Mortality Wave II Study (DMMS) patients who started
dialysis in 1996, and were followed until October 31 2001. Cox
regression analysis was used to model adjusted hazard ratios
(AHR) for mortality for categories of body mass index (BMI),
both as quartiles and as ≥30 kg/m2 vs. lower. Because such
a large proportion of peritoneal dialysis patients changed to
hemodialysis during the study period (45.5%), a sensitivity anal-
ysis was performed calculating survival time both censoring and
not censoring on the date of change from peritoneal dialysis to
hemodialysis.
Results. There were 1675 hemodialysis and 1662 peritoneal
dialysis patients. Among hemodialysis patients, 5-year survival
for patients with BMI ≥30 kg/m2 was 39.8% vs. 32.3% for lower
BMI (P < 0.01 by log-rank test). Among peritoneal dialysis
patients, 5-year survival for patients with BMI ≥30 kg/m2 was
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38.7% vs. 40.4% for lower BMI (P > 0.05 by log-rank test). In
adjusted analysis, BMI≥30 kg/m2 was associated with improved
survival in hemodialysis patients (AHR 0.89; 95% CI 0.81, 0.99;
P = 0.042) but not peritoneal dialysis patients (AHR = 0.99;
95% CI, 0.86, 1.15; P = 0.89). Results were not different on
censoring of change from peritoneal dialysis to hemodialysis.
Conclusion. We conclude that any survival advantage asso-
ciated with obesity among chronic dialysis patients is signifi-
cantly less likely for peritoneal dialysis patients, compared to
hemodialysis patients.
In contrast to the general population, obesity [defined
as a body mass index (BMI) ≥30 kg/m2] has generally
been associated with improved survival among chronic
hemodialysis patients, even after adjusting for differences
in dialysis adequacy [1–6]. However, previous studies lim-
ited to peritoneal dialysis patients have so far yielded
conflicting results regarding an association between obe-
sity and survival [7, 8]. Whether these discrepancies are
due to differences in populations studied, methodology,
sample size, or duration of follow-up has not been deter-
mined. The clinical importance of obesity is underscored
by its rapidly increasing prevalence in both the general
[9] and dialysis populations [10]. Obesity is also more
common among African Americans [9], who are over-
represented in the chronic dialysis population. Among
dialysis patients, obese African Americans may have im-
proved survival compared to obese Caucasians [11, 12].
A previous study, currently available only in abstract
form [abstract; Stack AG, et al, Am J Kidney Dis 41:A35
(abstract #95), 2003], has directly assessed the associa-
tion between BMI and survival between peritoneal dial-
ysis and hemodialysis patients. However, information on
factors recently shown to have significant associations
with survival, such as use of 3-hydroxy-3-methylglutaryl
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coenzyme A (HMG-CoA) reductase inhibitors [13], cal-
cium channel blockers [14], serum cholesterol levels [15],
and pulse pressure [16] were not available. The optimal
dialysis modality for obese patients who reach end stage
renal disease (ESRD), other than renal transplantation,
[17] has also not been determined.
To determine whether obesity has a significantly dif-
ferent association with survival in hemodialysis patients
compared to peritoneal dialysis patients, we conducted a
historical cohort study of the United States Renal Data
System (USRDS) Dialysis Morbidity and Mortality Wave
II (DMMS) database. Data collection was conducted as
a true prospective study of patients starting dialysis ther-
apy in 1996, with comparable numbers of hemodialysis
and peritoneal dialysis patients to facilitate comparisons
between dialysis modalities. The objective of the study
was to determine whether the association between obe-
sity and survival differed for hemodialysis vs. peritoneal
dialysis patients, and whether obese patients had differing
survival with one modality vs. another. The null hypothe-
sis was the association between BMI and survival was not
significantly different in hemodialysis patients compared
to peritoneal dialysis patients.
METHODS
Subjects
A retrospective cohort study of the USRDS DMMS
Wave II was performed; details of the studies performed
by the USRDS are described elsewhere [10]. Briefly, the
USRDS collects demographic and clinical data on pa-
tients who have survived more than 90 days on dialysis.
DMMS Wave II was a prospective cohort study that in-
cluded all eligible patients initiating peritoneal dialysis
and a 20% random sample of patients initiating hemodial-
ysis in 1996 and early 1997. This cohort was designed to
enable comparison of hemodialysis with peritoneal dialy-
sis patients. Since only a fraction of patients from the year
1997 were available, the present analysis included only
patients whose first date of ESRD was in 1996. Other de-
tails of the demographics and extraction of DMMS Wave
II have been described in other studies [18].
Data collection
As part of the USRDS cohort study, dialysis unit per-
sonnel performed chart reviews to obtain baseline and
follow-up patient data. Selected data for each patient at
the start of the study were as listed in Table 1. For peri-
toneal dialysis patients, BMI was calculated from height
at the start of the study period and the “dry weight,” as in-
dicated in the study questionnaire (which implied but did
not explicitly specify whether this meant without a fluid
dwell). For hemodialysis patients, weight for the calcu-
lation of BMI was obtained from the average of three
postdialysis weights (from the three most recent sessions
prior to the study start) since this is generally consid-
ered a better approximation of patient’s estimated dry
weight. In addition, a maximum of 15 medications pre-
scribed to each patient at the study start date (day 60 of
dialysis) were recorded in the DMMS Wave II database.
From this list, the use of angiotensin-converting enzyme
(ACE) inhibitors, beta blockers, calcium channel block-
ers, HMG-CoA reductase inhibitors, and aspirin was
determined. Carvedilol was approved for use by the fed-
eral Food and Drug Administration (FDA) in 1997 and
was therefore not assessed. Pre- and postdialysis blood
pressures, and intradialytic weight gains (hemodialysis
patients only) were averaged for three values determined
after the study start. Timing of blood pressure relative to
peritoneal dialysis exchanges was not specified. For this
reason, pulse pressure was calculated from predialysis
blood pressure readings only.
Outcome measurements
Survival status was linked to the DMMS Wave II data
from the USRDS patients Standard Analysis File (SAF)
via unique patient identifiers assigned by the USRDS.
The date and cause of death listed in a patient’s SAF
was obtained from a form submitted to the USRDS by
the patient’s nephrologist (formerly Health Care Finance
Authority, HCFA 2746). Patient survival status was com-
plete through October 31, 2001.
Although the DMMS Wave II data were collected at
day 60 after the first dialysis session, mortality was not
uniformly reported until 90 days after the first dialysis
session. Therefore, survival time was calculated as the
time from 90 days after the date of the first ESRD treat-
ment until the date of death, censored for the end of the
study or loss to follow-up. Although neither hemodialy-
sis nor peritoneal dialysis was independently associated
with survival, we performed a sensitivity analysis by cal-
culating survival time in two ways and measuring the ef-
fects separately: (1) censored upon change from either
peritoneal dialysis to hemodialysis or from hemodialy-
sis to peritoneal dialysis, and (2) not censored for such
changes. However, renal transplantation was significantly
associated with mortality. Since the assumptions of sur-
vival analysis prohibit censoring on variables that are
significantly associated with survival, due to possible in-
troduction of bias [19], renal transplantation was mod-
eled as a time-dependent covariate, similar to previous
analyses of this database [11, 12].
Statistical analysis
Univariate analysis was performed with chi-square
testing for categorical variables and Student t test for
continuous variables. Continuous variables that did not
have a normal distribution, namely serum parathy-
roid hormone (PTH) levels, were analyzed using the
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Table 1. Factors assessed in end-stage renal disease (ESRD) patients, Dialysis Morbidity and Mortality Wave II (DMMS Wave II), 1996
Peritoneal
Hemodialysis Missing dialysis Missing
Number 1675 1662
Body mass index kg/m2 26.3 ± 6.4 137 (8.2) 26.4 ± 5.5 39 (2.3)
Body mass index ≥30 kg/m2 352 (22.9) 357 (22.0)
Body mass index ≤19 kg/m2 120 (7.2) 89 (5.4)a
Mean age years 61.7 ± 15.6 5 (0.3) 56.3 ± 15.7b 10 (0.6)
Male 893 (53.3) 0 890 (53.5) 0
African American 565 (33.7) 0 358 (21.5)a 0
Ever transplanted (yes/no) 147 (8.8) Assumed 0 311 (18.7)a Assumed 0
Diabetes 847 (51.6) 33 (2.0) 808 (49.7) 35 (2.1)
Coronary heart disease 580 (37.6) 134 (8.0) 503 (32.3)a 107 (6.4)
Congestive heart failure 640 (40.8) 106 (6.3) 502 (31.8)a 82 (4.9)
Peripheral vascular disease 309 (20.0) 129 (7.7) 251 (16.1)a 100 (6.0)
Malnutrition 212 (13.9) 150 (9.0) 232 (15.4) 156 (9.4)
Smoking (current) 216 (13.8) 108 (6.4) 236 (15.3) 119 (7.2)
Continuous variables
Serum albumin g/dL 3.48 ± 0.58 117 (7.0) 3.41 ± 0.60b 187 (11.3)
Cholesterol mg/dL 180.0 ± 45.4 0 205.5 ± 51.8b 0
Hematocrit % 29.8 ± 5.7 45 (2.7) 31.3 ± 6.5b 39 (2.3)
Serum bicarbonate mg/dL 20.9 ± 6.6 117 (7.0) 23.7 ± 6.7b 179 (10.8)
Pulse pressure (using predialysis 73.1 ± 19.7 26 (1.6) 62.1 ± 20.0b 33 (2.0)
values for hemodialysis patients) mm Hg
Medications
Angiotensin-converting enzyme inhibitor 355 (21.2) Assumed 0 410 (24.7)a Assumed 0
Statin (3-hydroxy-3-methylglutaryl 100 (6.0) Assumed 0 174 (10.5)a Assumed 0
coenzyme A reductase inhibitor)
Calcium channel blocker 817 (48.8) Assumed 0 862 (51.3) Assumed 0
Aspirin 314 (18.7) Assumed 0 309 (18.6) Assumed 0
Beta blocker 290 (17.3) Assumed 0 348 (20.9)a Assumed 0
Functional status
Independent walking 1380 (83.3) 19 (1.1) 1538 (93.3)a 13 (0.8)
In column one, data given as the number (% of total) or mean ± one standard deviation. Values determined at 60 days after the start of dialysis.
aP < 0.05 by chi-square, peritoneal dialysis vs. hemodialysis; bP < 0.05 by Student t test, peritoneal dialysis vs. hemodialysis in mm Hg.
Mann-Whitney test. Missing values for continuous vari-
ables were analyzed in two ways: both as truly missing
and as set to the mean of the variable, while missing val-
ues for categorical variables were presumed to be ab-
sent, as in previous investigations of the USRDS [20].
Kaplan-Meier analysis was used to plot unadjusted sur-
vival of peritoneal dialysis and hemodialysis patients by
categories of BMI (as categories of ≥30 kg/m2 vs. lower
and as quartiles; narrower categories of BMI were not
practical due to sample size limitations).
Variables with P < 0.10 in univariate analysis for an
association with mortality were entered into multivariate
analysis as covariates. An exception was made for fac-
tors thought to have a clinical reason to be associated
with mortality, in accordance with established epidemio-
logic principles [21]. These included ACE inhibitors, cal-
cium channel blockers, beta blockers, BMI, race, gender,
coronary heart disease, hematocrit, and ESRD network
(to assess for regional differences). Information on urine
volume was missing for the majority of patients, and thus
calculation of residual renal function was not performed.
Likewise, dialysis adequacy was not comparable between
patients undergoing hemodialysis vs. patients on peri-
toneal dialysis.
Stepwise Cox proportional hazards model for censored
survival data was used to assess the association between
baseline factors and time to mortality, independent of
other predictors. Adjustment variables were chosen for
the multivariate regression model based on the possibility
that the covariate of interest was either significant in uni-
variate analysis or had clinical evidence of a relationship
to the risk of mortality, as above. Log-log plots were in-
spected to verify the existence of proportional hazards. In
Cox regression of analysis of the cohort of USRDS pa-
tients who started dialysis in 1996 who had valid BMI,
covariates in analysis included BMI (as categories of
≥30 kg/m2 vs. lower and as quartiles), patient age, race,
gender, diabetes as a causes of renal failure (yes/no), and
a history of congestive heart failure, ischemic heart dis-
ease, peripheral vascular disease, pulse pressure, ability
to walk independently, quartiles of serum albumin and
cholesterol levels, presence of malnutrition (subjective
impression), renal transplantation (as a time-dependent
variable), and use of aspirin, ACE inhibitors, beta block-
ers, calcium channel blockers, and HMG-CoA reductase
inhibitors. A separate stratified analysis was performed
of factors associated with survival for patients with BMI
≥30 kg/m2.
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RESULTS
A total of 4065 patients were included in the DMMS
Wave II cohort. Of these, 3621 patients had valid dates
for starting dialysis in 1996. From this cohort, 3374 had
sufficient information to calculate follow-up times. Of the
1662 patients who started out on peritoneal dialysis, 757
(45.5%) changed to hemodialysis for 60 consecutive days
at least once during the study period. The mean time
to the earliest switch from hemodialysis to peritoneal
dialysis was 2.05 ± 1.30 years. The rate of change to
hemodialysis from peritoneal dialysis was constant over
time. A change from peritoneal dialysis to hemodialysis
was more frequent among patients with a higher quar-
tile of BMI (47.1% among those in the highest quar-
tile of BMI vs. 41.8% for those in the lowest quartile of
BMI), but this was not statistically significant (P = 0.64
by chi-square). Among the 1675 hemodialysis patients, 71
(4.2%) changed to peritoneal dialysis for 60 days at least
once during the study period. After exclusion of missing
values and values not thought to be biologically plausi-
ble, BMI could be calculated for 91.8% of hemodialysis
patients and for 97.7% of peritoneal dialysis patients.
Characteristics of the study population are summa-
rized in Table 1. In unadjusted analysis, there were many
differences between hemodialysis and peritoneal dialy-
sis patients despite the attempts of the DMMS Wave
II database to create a “matched” population by dialy-
sis modality. At 60 days after the start of dialysis, peri-
toneal dialysis was significantly associated with a lower
frequency of African American patients, younger age,
increased rate of renal transplantation, decreased preva-
lence of coronary heart disease and congestive heart
failure, lower prevalence of stroke, peripheral vascular
disease, left ventricular hypertrophy on ECG, and can-
cer, decreased use of erythropoietin, and higher levels of
cholesterol, hematocrit, bicarbonate, lower pulse pres-
sure, and higher rates of use of ACE inhibitors, HMG-
CoA reductase inhibitors, and beta blockers. However,
BMI was not significantly different between hemodial-
ysis and peritoneal dialysis patients when assessed as a
continuous variable. Values for serum calcium, phospho-
rous, and PTH were not significantly different between
hemodialysis and peritoneal dialysis patients and have
been reported previously [19].
Figure 1 shows a histogram of BMI among hemodial-
ysis patients, with results similar to those reported pre-
viously [22]. Figure 2 shows a histogram of BMI among
peritoneal dialysis patients. In comparison, the BMI dis-
tribution among hemodialysis patients showed more left-
ward skewing (skew 0.96) compared to peritoneal dialysis
patients (skew 0.81).
Among hemodialysis patients, 1100 (65.7%) died dur-
ing the study period. Censoring hemodialysis patients
who later changed to peritoneal dialysis reduced the to-
tal number of deaths to 1064 (63.5%). Figure 3 shows a
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Fig. 1. Histogram of body mass index (BMI) of hemodialysis patients
with valid BMI.
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Fig. 2. Histogram of body mass index (BMI) of peritoneal dialysis pa-
tients with valid BMI.
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Fig. 3. Kaplan-Meier plot of patient survival by quartile of body mass
index (BMI) in kg/m2, hemodialysis patients only, Dialysis Morbidity
and Mortality Wave II (DMMS Wave II). Patients in the lowest two
quartiles of BMI consistently had the worst survival, while those in
the highest two quartiles had equivalent survival after approximately
2 years. Quartiles of BMI = 4 (>29.9), 3(>25.0–29.9), 2(21.9–24.9),
1(<21.9). Quartile of BMI 1 P < 0.01 by log-rank test vs. highest quartile.
Kaplan-Meier plot of survival time by quartile of BMI for
hemodialysis patients. As shown, hemodialysis patients
in the lowest quartile of BMI consistently had the worst
survival during the course of the study. However, early
in the study, hemodialysis patients in the third quartile
of BMI had the best survival, while after 2 years survival
for hemodialysis patients in the third and fourth quar-
tiles of BMI became equivalent. However, survival was
consistently higher for hemodialysis patients with BMI
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Fig. 4. Kaplan-Meier plot of patient survival by body mass index (BMI)
≥ 30 kg/m2 or less, hemodialysis patients only, Dialysis Morbidity and
Mortality Wave II (DMMS Wave II). Patients with BMI ≥ 30 kg/m2
had improved survival compared to those with lower BMI, P < 0.01 by
log-rank test.
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Fig. 5. Kaplan-Meier plot of patient survival by quartile of body mass
index (BMI) in kg/m2, peritoneal dialysis patients only, Dialysis Mor-
bidity and Mortality Wave II (DMMS Wave II). Patients in the lowest
quartile of BMI had the lowest survival, but this was not statistically
significant (P = 0.09 by Log Rank test vs. highest quartile). Quartiles
of BMI = 4 (>29.5), 3(>25.7–29.5), 2(22.4–25.7), 1(<22.4).
≥30 kg/m2 (vs. lower BMI) over time (Fig. 4) (P < 0.01
by log-rank test).
Among peritoneal dialysis patients, 989 (59.5%) died
during the period of the study. Censoring of peritoneal
dialysis patients who later changed to hemodialysis re-
duced the total number of deaths to 585 (35.2%). How-
ever, the graphic relationship between BMI and death
did not change, regardless of censoring strategy. For peri-
toneal dialysis patients, Figure 5 (which did not censor
on change from peritoneal dialysis to hemodialysis) and
Figure 6 (which did censor on change from peritoneal
dialysis to hemodialysis) show a similar Kaplan-Meier
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Fig. 6. Analysis from Fig. 5 censored for change to hemodialysis
showed a lower rate of death overall, but a similar relationship between
body mass index (BMI) and survival.
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Fig. 7. Kaplan-Meier plot of patient survival by body mass index (BMI)
≥30 kg/m2 or less, peritoneal dialysis patients only, Dialysis Morbidity
and Mortality Wave II (DMMS Wave II). Patients with BMI ≥30 kg/m2
did not have improved survival compared to those with lower BMI,
P > 0.05 by log-rank test.
plot of survival time by quartile of BMI. As shown,
only peritoneal dialysis patients in the lowest quartile of
BMI were at increased risk of mortality, while peritoneal
dialysis patients in BMI second to fourth quartiles had
virtually identical risk of death over time. Results of
analysis censored for peritoneal dialysis patients who
later changed to hemodialysis was essentially the same.
Figure 7 (which did not censor on change from peritoneal
dialysis to hemodialysis) and Figure 8 (which did cen-
sor on change from peritoneal dialysis to hemodialysis)
show that, in contrast, the survival of peritoneal dialy-
sis patients with BMI ≥30 kg/m2 was essentially equiva-
lent to that of peritoneal dialysis patients with lower BMI
throughout the study, which was unchanged for censoring
on change from peritoneal dialysis to hemodialysis.
BMI ≥30 kg/m2 was independently associated with im-
proved survival in Cox regression analysis of the entire
cohort of DMMS Wave II patients. However, there was a
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Fig. 8. Analysis from Fig. 7 censored for change to hemodialysis
showed a lower rate of death overall, but a similar relationship between
BMI and survival.
Table 2. Cox regression of factors associated with mortality
(multivariate), hemodialysis patients only
Adjusted
hazards
P value ratio 95% CI
Body mass index ≥30 kg/m2 0.042 0.89 0.81, 0.99
Quartiles of body mass index
<21.9 0.001 1.41 1.15, 1.71
21.9–24.9 0.057 1.21 0.99, 1.46
25.0–29.9 0.61 0.95 0.78, 1.16
>29.9 Reference 1.00
Age (per 10 years) <0.0001 1.22 1.17, 1.28
African American race .003 0.79 0.68, 0.93
Malnutrition <0.001 1.42 1.17, 1.73
Peripheral vascular disease 0.004 1.28 1.08, 1.51
Coronary heart failure <0.001 1.39 1.20, 1.61
Serum albumin <0.001 0.84 0.78, 0.89
(per higher quartile)
Independent walking <0.001 0.73 0.60, 0.88
Renal transplantation <0.001 0.16 0.09, 0.29
(time dependent)
Number in final sample 1295
Only factors significant in the final model are shown. Interpolated values
substituted the mean values for continuous variables with missing values.
significantly adverse interaction between BMI ≥30 kg/m2
and patients on peritoneal dialysis, such that peritoneal
dialysis was a significant modifier of the effect of obesity
on survival [P = 0.001; adjusted hazard ratio (AHR) 1.41;
95% CI 1.06, 1.88). Therefore, further analysis of the co-
hort including both peritoneal dialysis and hemodialysis
patients was inappropriate, and further analysis was strat-
ified separately for peritoneal dialysis and hemodialysis
patients. Other factors significantly associated with mor-
tality in the cohort were similar to those reported previ-
ously [14].
Table 2 shows results of Cox regression analysis of fac-
tors associated with survival for hemodialysis patients
only. In the interpolated model, BMI ≥30 kg/m2 was
significantly associated with improved survival, although
only at the margin of statistical significance. Factors that
were associated with reduced mortality were use of cal-
cium channel blockers, higher serum albumin levels, and
renal transplantation. Older age, malnutrition, periph-
eral vascular disease, coronary heart disease, congestive
heart failure, and use of a temporary catheter were asso-
ciated with increased mortality. When BMI was assessed
as quartiles, hemodialysis patients in the lowest quartile
of BMI were at independently greater risk of mortality
compared to those in the highest quartile of BMI. In the
noninterpolated model, BMI ≥30 kg/m2 was not signif-
icantly associated with reduced mortality in this cohort
(P = 0.08 in Cox regression).
Table 3 shows results of Cox regression analysis of
factors associated with survival for peritoneal dialysis
patients only. When BMI was assessed as quartiles, peri-
toneal dialysis patients in the lowest quartile of BMI were
at independently greater risk of mortality compared to
those in the highest quartile of BMI. Use of interpolated
values did not affect the significance of BMI for peri-
toneal dialysis patients. In analysis using survival values
censored for change of modality to hemodialysis, how-
ever, peritoneal dialysis patients in the lowest quartile
of BMI were no longer at independently increased risk
of morality compared to those in the highest quartile of
BMI, as shown in the right columns. No other quartiles of
BMI were significantly associated with mortality in com-
parison with the highest quartile of BMI.
There were no significant interactions between BMI
and either race or gender. In stratified analysis limited to
patients with BMI ≥30 kg/m2 (total number in model =
519), peritoneal dialysis (vs. hemodialysis) was not signifi-
cantly associated with mortality (AHR 1.23; 95% CI 0.82,
1.85; P = 0.31), and there was no significant interaction
between peritoneal dialysis and diabetes.
DISCUSSION
The present study shows that low BMI was indepen-
dently associated with increased risk of death regardless
of dialysis modality. However, the association between
high BMI and survival in chronic dialysis patients dif-
fers significantly by dialysis modality. While there were
many differences in the characteristics of hemodialysis
and peritoneal dialysis patients, most differences were
clinically modest even if statistically significant, consis-
tent with previous reports [23–25]. As shown in Figures 3
to 8 and as a significant interaction term with BMI in
Cox regression analysis, peritoneal dialysis was an in-
dependent effect modifier of the association between
obesity with survival. This can be interpreted as mean-
ing that any potentially beneficial association between
obesity and survival is less likely in peritoneal dialysis
patients than in hemodialysis patients, and that the asso-
ciation of BMI with mortality should be presented sep-
arately for hemodialysis and peritoneal dialysis patients,
in agreement with previous reports of the entire USRDS
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Table 3. Cox regression of factors associated with mortality (multivariate), peritoneal dialysis patients only
Survival not censored Survival censored
on change to hemodialysis on change to hemodialysis
Adjusted hazards Adjusted hazards
P value ratio 95% CI P value ratio 95% CI
Body mass index ≥30 kg/m2 0.89 0.99 0.86, 1.15 0.77 1.03 0.86, 1.22
Quartiles of BMI
<22.4 0.012 1.32 1.07, 1.65 0.36 1.12 0.88, 1.42
22.4–25.7 0.98 1.00 0.81, 1.23 0.26 0.88 0.69, 1.11
>25.7–29.5 0.79 1.03 0.83, 1.27 0.52 0.93 0.74, 1.16
>29.5 Reference 1.00 Reference 1.00
Number in final sample 1274
Both models also adjusted for age, race (African American versus all others), gender, use of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors,
aspirin, calcium channel blockers, angiotensin-converting enzyme inhibitors, serum hemoglobin, serum albumin, diabetes, malnutrition (as a subjective diagnosis), prior
history of congestive heart failure and ischemic heart disease, smoking history, and renal transplantation as a time-dependent variable (models were also performed
censoring for the date of renal transplantation, with results not substantially different from those shown above).
Interpolated values substituted the mean values for continuous variables with missing values.
population. We report that this finding persists in longer
follow-up and adjusting for other important factors that
might confound associations with survival, including per-
tinent laboratory and blood pressure data, medication
use, and change of dialysis modality. We found that
peritoneal dialysis (vs. hemodialysis) was not signifi-
cantly associated with mortality in obese dialysis pa-
tients, although sample size was relatively small for this
subgroup.
The association between BMI and survival in
hemodialysis patients has been widely studied. Reports
for peritoneal dialysis have been less numerous. Two pre-
vious studies, by Johnson et al [8] and Aslam et al [7],
apparently contradicted each other, perhaps due to dif-
ferences in study design. While both previous studies
used BMI categories derived from the general popula-
tion, weight categories may be useful only for comparing
the relationship between BMI and survival in the gen-
eral population with patients on dialysis, and for mod-
eling an association between BMI and survival among
dialysis populations. This is the reason we used quartiles
of BMI in addition to a priori categorizations of obesity
in the present study. In the study of Johnson et al [8], a
BMI ≥27.5 was associated with an AHR of 0.09 (95% CI
0.01, 0.85) for mortality in comparison to patients with a
lower BMI. This is more than a tenfold lower adjusted
risk of mortality, which was certainly not seen in the
present study, and is difficult to explain based on clinical
experience.
Regardless of initial dialysis modality, any protective
effect of obesity on survival is not apparent after renal
transplantation [26], and obese dialysis patients have im-
proved survival after renal transplantation [17]. This sug-
gests a direct effect of dialysis modality on the association
between obesity and survival.
Why would survival of obese patients differ by dialy-
sis modality? It appears that low BMI is associated with
increased mortality in both hemodialysis and peritoneal
dialysis, despite the finding of most studies that such pa-
tients have higher dialysis adequacy [27, 28]. Therefore,
the specific question is, why would obesity be beneficial
in hemodialysis but not peritoneal dialysis? Obese pa-
tients may be more likely underdialyzed on peritoneal
dialysis than on hemodialysis. In fact, body size has been
a limiting factor for consideration of peritoneal dialysis
as a choice of modality, although no firm “cutoff” size
is now specified in current Kidney/Dialysis Outcomes
Quality Initiative (K/DOQI) guidelines, so long as pa-
tients achieve measured adequacy, which appears possi-
ble for obese peritoneal dialysis patients [29]. Although
the importance of achieving adequacy has been brought
into question by the recent ADEMEX study [30], the
lack of adequate data on dialysis adequacy for most pa-
tients in the DMMS Wave II cohort is a definite limitation
of the current study. While the ADEMEX and HEMO
studies [31], of peritoneal dialysis and hemodialysis,
respectively, were both landmark clinical trials, each had
disproportionately few obese patients. Each also contra-
dicted findings from previous observational trials. It has
been very difficult to show an impact of peritoneal dialysis
adequacy (nonrenal), or body size, or in fact of any factor
except residual renal function on survival of peritoneal
dialysis patients [32–34], a dilemma that continues to defy
explanation. Some authors have speculated on differ-
ent mechanisms of malnutrition in patients with chronic
kidney disease, namely “uremic” malnutrition and “in-
flammatory” malnutrition associated with prevalent car-
diovascular disease [35]. Whether these factors differ by
dialysis modality has not been established. Hemodialysis
has been associated with increased inflammatory activ-
ity [36, 37]. However, it is difficult to compare markers
of inflammation, such as C-reactive protein (CRP), be-
tween peritoneal dialysis and hemodialysis because of the
dramatic effect of the timing of hemodialysis and inter-
current events (such as vaccinations) on such markers
[38]. Unfortunately, anthropometric measures correlate
poorly with inflammatory cytokines in hemodialysis
patients [39].
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Comparisons of survival between hemodialysis and
peritoneal dialysis must carefully account for differences
in baseline comorbid conditions, as emphasized in pre-
vious reports [10, 24], as well as account for possible
changes in modality-associated mortality over time [40].
Limitations of the DMMS Wave II database in compar-
ison to other cohorts such as the CHOICE cohort [41]
have been noted. We were unable to follow changes
in variables over time. Therefore, we could not follow
changes in blood pressure, laboratory values, or dial-
ysis adequacy. This most especially applied to possi-
ble changes in medication use and changes in patient
dry weight. Because such a high proportion (45%) of
peritoneal dialysis patients changed modality during the
course of the study, calculation of survival time was sub-
ject to potential bias, whether or not patients were cen-
sored at the time of changing modality to hemodialysis.
Bias attributable to not censoring on change to hemodial-
ysis included potentially differing effects of hemodialy-
sis on mortality once modality was changed. However,
bias could also be introduced by censoring patients upon
change to hemodialysis. Such patients would most likely
have had substantial declines in residual renal function,
frequent bouts of peritonitis, or other conditions that
would place them at risk of increased mortality. It is pos-
sible that these conditions were directly attributable to
peritoneal dialysis as a modality, although the DMMS
Wave II database could not ascertain this with certainty.
Therefore, censoring of these patients removed a substan-
tial number of patients who died prematurely. In fact,
in analysis censoring peritoneal dialysis patients upon
change to hemodialysis, patients with low BMI were no
longer independently at increased risk of death, possi-
bly due to the bias described above. However, in both
methods of estimating survival times, a high BMI had
a neutral association with mortality in peritoneal dialysis
patients, which strengthens the finding of this association.
We would emphasize that these findings are only associ-
ations, and should not be construed to be causative. As
mentioned previously, both the HEMO and ADEMEX
trials contradicted earlier observational trials; however,
it is unlikely the HEMO or ADEMEX trials would have
been performed in the absence of those observational
trials.
However, DMMS Wave II has some unique advan-
tages. BMI could be calculated from postdialysis weights
for hemodialysis patients and on weights 60 days after the
start of dialysis for all patients; as such, they may more
accurately reflect patient “dry” weight than weights ob-
tained at presentation to ESRD, as reported in CMS Form
2728 (the Medical Evidence Form). Pulse pressure, not
available from the Medical Evidence Form, has also been
an independent predictor of mortality in other studies of
hemodialysis patients [15], but not in peritoneal dialysis
patients [42]. Differences in blood pressure patterns and
their possible impact on residual renal function may in
part be responsible. In addition, medication use, also not
available from the Medical Evidence Form, has also been
independently associated with survival in this cohort [13,
14]. As far as we are aware, previous studies assessing the
impact of BMI and dialysis modality on survival have not
assessed for all these factors.
CONCLUSION
Patients with low BMI are at increased risk of death re-
gardless of dialysis modality. However, the relationship
between obesity and survival differs by dialysis modality
for reasons that have yet to be determined. In fact, obe-
sity has a neutral impact on survival among peritoneal
dialysis patients, in contrast to its beneficial association
in hemodialysis patients; conversely, among obese dialy-
sis patients, peritoneal dialysis is associated with a higher,
but statistically insignificant, risk of mortality.
NOTE ADDED IN PROOF
We would like to acknowledge the recent paper by
Syder et al (Kidney Int 64:1838–1844, 2003), which per-
formed an analysis of the relationship between BMI and
survival among PD patients for the entire population of
U.S PD patients from 1995 to 2000. Our results are ac-
tually quite similar, and we would emphasize that the
survival advantage associated with obesity among PD pa-
tients the authors concluded from their study was only
seen in the first year of dialysis, not unlike our Figures
5–7, and that this advantage, while statistically significant
(relative risk of 0.89). Study design differences between
the Snyder et al study and ours are, of course, emphasized
in our discussion.
Reprint requests to Kevin C. Abbott, LTC, MC, Nephrology Service,
Walter Reed Army Medical Center, Washington, DC 20307-5001.
E-mail: kevin.abbott@na.amedd.army.mil
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